New Target, New Drug, Old Paradigm
- 15 June 2004
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (12), 2270-2272
- https://doi.org/10.1200/jco.2004.03.918
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With CancerJournal of Clinical Oncology, 2004
- Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell CarcinomaJournal of Clinical Oncology, 2004
- Antitumor Efficacy of Intermittent Treatment Schedules with the Rapamycin Derivative RAD001 Correlates with Prolonged Inactivation of Ribosomal Protein S6 Kinase 1 in Peripheral Blood Mononuclear CellsCancer Research, 2004
- Will mTOR inhibitors make it as cancer drugs?Cancer Cell, 2003
- Mammalian Target of Rapamycin: A New Molecular Target for Breast CancerClinical Breast Cancer, 2003
- Rapamycins: mechanism of action and cellular resistance.Cancer Biology & Therapy, 2003
- Clinical development of mammalian target of rapamycin inhibitorsHematology/Oncology Clinics of North America, 2002
- An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity inPten+/−miceProceedings of the National Academy of Sciences, 2001
- Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTORProceedings of the National Academy of Sciences, 2001
- The rapamycin-sensitive signal transduction pathway as a target for cancer therapyOncogene, 2000